Advertisement



Drug Shortages

Last updated

Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.

240 medicines

  • Ciprofloxacin Hydrochloride and Hydrocortisone Being discontinued 1 product · updated October 30, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Cipro, Otic Suspension/Drops, 0.2% base, 1% (NDC 66758-087-70)
    Sandoz Inc.    		 Discontinuation of the manufacturing of NDC 66758-087-70. Authorized generic is available under new NDC 0781-6218-70
    Being discontinued · October 30, 2026

    Uses, warnings and side effects from the FDA label →

  • Bupivacaine Hydrochloride In shortage Some forms unavailable 68 products · updated October 29, 2026

    Anesthesia, Analgesia/Addiction

    Product Availability Expected supply / notes
    Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)
    Huons Co., Ltd    		 Unavailable Estimated recovery: TBD
    In shortage · July 30, 2026
    Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 29, 2026
    Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)
    Kindos Pharmaceuticals Co. Ltd.    		 Limited Meitheal Pharmaceuticals is distributor/labeler
    In shortage · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)
    Kindos Pharmaceuticals Co. Ltd.    		 Limited Meitheal Pharmaceuticals is distributor/labeler
    In shortage · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)
    Kindos Pharmaceuticals Co. Ltd.    		 Limited Meitheal Pharmaceuticals is distributor/labeler
    In shortage · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)
    Kindos Pharmaceuticals Co. Ltd.    		 Limited Meitheal Pharmaceuticals is distributor/labeler
    In shortage · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)
    Kindos Pharmaceuticals Co. Ltd.    		 Limited Meitheal Pharmaceuticals is distributor/labeler
    In shortage · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)
    Kindos Pharmaceuticals Co. Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)
    Kindos Pharmaceuticals Co. Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)
    Kindos Pharmaceuticals Co. Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)
    Kindos Pharmaceuticals Co. Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 5, 2026
    Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)
    Kindos Pharmaceuticals Co. Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 5, 2026

    + 53 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Bupivacaine Hydrochloride and Epinephrine In shortage Some forms unavailable 12 products · updated October 29, 2026

    Anesthesia, Analgesia/Addiction

    Product Availability Expected supply / notes
    Bupivacaine Hydrochloride with Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 29, 2026
    Bupivacaine Hydrochloride with Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 29, 2026
    Bupivacaine Hydrochloride with Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 29, 2026
    Bupivacaine Hydrochloride with Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 29, 2026
    Bupivacaine Hydrochloride with Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 29, 2026
    Bupivacaine Hydrochloride with Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 29, 2026

    + 6 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Methotrexate In shortage Some forms unavailable 13 products · updated October 29, 2026

    Rheumatology, Oncology

    Product Availability Expected supply / notes
    Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)
    Accord Healthcare Inc.    		 Unavailable Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: Jan 2027
    In shortage · October 17, 2026
    Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)
    Teva Pharmaceuticals USA, Inc.    		 Unavailable Estimated Recovery: Novemeber 2026
    In shortage · October 15, 2026
    Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Additional lots will be available in the November 2026 timeframe. Short Dated Prodcut Available.
    In shortage · October 14, 2026
    Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.
    In shortage · October 14, 2026
    Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)
    Teva Pharmaceuticals USA, Inc.    		 Limited Estimated recovery: October 2026
    In shortage · October 15, 2026
    Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)
    Teva Pharmaceuticals USA, Inc.    		 Limited Estimated recovery: October 2026
    In shortage · October 15, 2026

    + 7 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Midazolam Hydrochloride In shortage Some forms unavailable 25 products · updated October 29, 2026

    Anesthesia, Neurology

    Product Availability Expected supply / notes
    Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: November 2026; Estimated Recovery: December 2026
    In shortage · October 29, 2026
    Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: November 2026; Estimated Recovery: December 2026
    In shortage · October 29, 2026
    Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: January 2027; Estimated Recovery: March 2027
    In shortage · October 29, 2026
    Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)
    Gland Pharma Limited    		 Unavailable Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals
    In shortage · October 21, 2026
    Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)
    Gland Pharma Limited    		 Unavailable Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals
    In shortage · October 21, 2026
    Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)
    Fresenius Kabi USA, LLC    		 Unavailable Next release November 2026. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: December 2026; Estimated Recovery: March 2027
    In shortage · October 29, 2026
    Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)
    Hospira, Inc., a Pfizer Company    		 Limited Next Estimated Delivery and Estimated Recovery: December 2026
    In shortage · October 29, 2026
    Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: March 2027
    In shortage · October 29, 2026

    + 14 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Sterile Water In shortage Some forms unavailable 13 products · updated October 29, 2026

    Other

    Product Availability Expected supply / notes
    Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)
    Fresenius Kabi USA, LLC    		 Unavailable Next release October 2026. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
    In shortage · October 14, 2026
    Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)
    Nephron Pharmaceuticals Corporation    		 Limited Small amount of inventory available with 12/31/2026 dating
    In shortage · August 4, 2026

    + 10 more products listed, currently available.

  • Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate In shortage Some forms unavailable 49 products · updated October 28, 2026

    Psychiatry

    Product Availability Expected supply / notes
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)
    Granules Pharmaceuticals Inc.    		 Unavailable Estimated recovery: December 2026
    In shortage · October 28, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)
    Granules Pharmaceuticals Inc.    		 Unavailable Estimated recovery: November 2026
    In shortage · October 28, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)
    Granules Pharmaceuticals Inc.    		 Unavailable Estimated recovery: November 2026
    In shortage · October 28, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)
    Granules Pharmaceuticals Inc.    		 Unavailable Estimated recovery: November 2026
    In shortage · October 28, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)
    Granules Pharmaceuticals Inc.    		 Unavailable Estimated recovery: December 2026
    In shortage · October 28, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)
    Granules Pharmaceuticals Inc.    		 Unavailable Estimated recovery: November 2026
    In shortage · October 28, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)
    Granules Pharmaceuticals Inc.    		 Unavailable Estimated recovery: November 2026
    In shortage · October 28, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)
    Oryza Pharmaceuticals Inc.    		 Unavailable Estimated recovery: April 2027
    In shortage · October 15, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)
    Oryza Pharmaceuticals Inc.    		 Unavailable Estimated recovery: April 2027
    In shortage · October 15, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)
    Oryza Pharmaceuticals Inc.    		 Unavailable Estimated recovery: April 2027
    In shortage · October 15, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)
    Oryza Pharmaceuticals Inc.    		 Unavailable Estimated recovery: April 2027
    In shortage · October 15, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)
    Oryza Pharmaceuticals Inc.    		 Unavailable Estimated recovery: April 2027
    In shortage · October 15, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)
    Aurobindo Pharma USA    		 Unavailable Estimated availability: April 2027
    In shortage · October 2, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)
    Aurobindo Pharma USA    		 Unavailable Estimated availability: April 2027
    In shortage · October 2, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)
    Aurobindo Pharma USA    		 Unavailable Estimated availability: April 2027
    In shortage · October 2, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)
    Aurobindo Pharma USA    		 Unavailable Estimated availability: April 2027
    In shortage · October 2, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)
    Aurobindo Pharma USA    		 Unavailable Estimated availability: April 2027
    In shortage · October 2, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)
    Aurobindo Pharma USA    		 Unavailable Estimated availability: April 2027
    In shortage · October 2, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)
    Epic Pharma, LLC    		 Limited Estimated recovery: TBD
    In shortage · October 23, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)
    Epic Pharma, LLC    		 Limited Estimated recovery: TBD
    In shortage · October 23, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)
    Epic Pharma, LLC    		 Limited Estimated recovery: TBD
    In shortage · October 23, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)
    Epic Pharma, LLC    		 Limited Estimated recovery: TBD
    In shortage · October 23, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)
    Epic Pharma, LLC    		 Limited Estimated recovery: TBD
    In shortage · October 23, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)
    Teva Pharmaceuticals USA, Inc.    		 Limited Estimated recovery: TBD
    In shortage · October 15, 2026

    + 25 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Atropine Sulfate In shortage Some forms unavailable 18 products · updated October 27, 2026

    Anesthesia, Neurology, Pediatric

    Product Availability Expected supply / notes
    Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)
    Accord Healthcare Inc.    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · October 17, 2026
    Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)
    Accord Healthcare Inc.    		 Unavailable Estimated availability: November/December 2026
    In shortage · October 17, 2026
    Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)
    Accord Healthcare Inc.    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · October 17, 2026
    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)
    Fresenius Kabi USA, LLC    		 Unavailable Next release October 2026. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: TBD
    In shortage · October 3, 2026
    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: mid-September 2026
    In shortage · September 1, 2026
    Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)
    Hospira, Inc., a Pfizer Company    		 Limited Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)"
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025
    Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)"
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025

    + 9 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Atropine Sulfate Monohydrate In shortage 1 product · updated October 27, 2026

    Anesthesia, Neurology, Pediatric

    Product Availability Expected supply / notes
    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)
    Somerset Therapeutics, LLC    		 Available —
    In shortage · October 27, 2026

    Uses, warnings and side effects from the FDA label →

  • Dexamethasone Sodium Phosphate In shortage Some forms unavailable 19 products · updated October 27, 2026

    Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology

    Product Availability Expected supply / notes
    Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)
    Fresenius Kabi USA, LLC    		 Unavailable Next release January 2027. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)
    Fresenius Kabi USA, LLC    		 Unavailable Next release October 2026. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)
    Fresenius Kabi USA, LLC    		 Unavailable Next release January 2027. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Product temporarily on backorder. Additional lots will be available in the November 2026 timeframe.
    In shortage · October 14, 2026

    + 15 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Dexmedetomidine Hydrochloride In shortage Some forms unavailable 52 products · updated October 27, 2026

    Anesthesia

    Product Availability Expected supply / notes
    Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)
    Par Health, USA LLC    		 Unavailable Estimated recovery: TBD; Please check wholesalers for inventory
    In shortage · October 15, 2026
    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)
    Fresenius Kabi USA, LLC    		 Unavailable Expected recovery: TBD
    In shortage · October 15, 2026
    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)
    Par Health, USA LLC    		 Unavailable Estimated recovery: TBD; Please check wholesalers for inventory
    In shortage · October 15, 2026
    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)
    Fresenius Kabi USA, LLC    		 Unavailable Expected recovery: TBD
    In shortage · October 15, 2026
    Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)
    Par Health, USA LLC    		 Unavailable Please check wholesalers for inventory
    In shortage · October 15, 2026
    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)
    Accord Healthcare Inc.    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · September 15, 2026
    Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)
    Pfizer Inc.    		 Limited Limited Supply Available. Next Delivery and Estimated Recovery: December 2026
    In shortage · October 21, 2026
    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)
    Slayback Pharma    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 5, 2026
    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)
    Slayback Pharma    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 5, 2026

    + 41 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Dextrose Monohydrate In shortage Some forms unavailable 57 products · updated October 27, 2026

    Endocrinology/Metabolism, Gastroenterology, Pediatric, Other

    Product Availability Expected supply / notes
    Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: November 2026. Estimated Recovery: March 2027. Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 27, 2026
    Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)
    Otsuka ICU Medical LLC    		 Unavailable Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
    In shortage · October 16, 2026
    Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)
    Baxter Healthcare    		 Unavailable Estimated recovery: December 2026
    In shortage · October 16, 2026
    Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)
    Baxter Healthcare    		 Unavailable Estimated recovery: November 2026
    In shortage · October 16, 2026
    Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)
    Hospira, Inc., a Pfizer Company    		 Limited Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 27, 2026
    Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)
    Amphastar Pharmaceuticals, Inc.    		 Limited Demand increase for the drug
    In shortage · October 16, 2026
    Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34)
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025

    + 50 more products listed, currently available.

  • Furosemide In shortage Some forms unavailable 32 products · updated October 27, 2026

    Cardiovascular

    Product Availability Expected supply / notes
    Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)
    Gland Pharma Limited    		 Unavailable Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product
    In shortage · October 21, 2026
    Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)
    Gland Pharma Limited    		 Unavailable Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product
    In shortage · October 21, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)
    Gland Pharma Limited    		 Unavailable Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product
    In shortage · October 21, 2026
    Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)
    Eugia US LLC    		 Unavailable On backorder. Recovery: TBD. Check wholesalers for inventory
    In shortage · October 19, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: TBD/ NDC non-Exempt
    In shortage · October 17, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: TBD/ NDC non-Exempt
    In shortage · October 17, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: TBD/ NDC non-Exempt
    In shortage · October 17, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)
    Avet Pharmaceuticals, Inc.    		 Unavailable Estimated recovery: end October 2026
    In shortage · October 15, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)
    Gland Pharma Limited    		 Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
    Being discontinued · April 28, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)
    Gland Pharma Limited    		 Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
    Being discontinued · April 28, 2026
    Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)
    Gland Pharma Limited    		 Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
    Being discontinued · April 28, 2026

    + 18 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Ropivacaine Hydrochloride In shortage Some forms unavailable 49 products · updated October 27, 2026

    Anesthesia

    Product Availability Expected supply / notes
    Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)
    Eugia US LLC    		 Unavailable On backorder. Recovery: TBD. Check wholesalers for inventory
    In shortage · October 19, 2026
    Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)
    Eugia US LLC    		 Unavailable On backorder. Recovery: TBD. Check wholesalers for inventory
    In shortage · October 19, 2026
    Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)
    Fresenius Kabi USA, LLC    		 Unavailable Next release not available at this time. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)
    Fresenius Kabi USA, LLC    		 Unavailable Estimated recovery: TBD
    In shortage · October 15, 2026
    Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)
    InfoRLife SA    		 Unavailable Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals
    In shortage · October 6, 2026
    Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)
    Caplin Steriles, Ltd.    		 Limited Check wholesalers for inventory; Marketed by Baxter
    In shortage · June 10, 2026
    Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)
    Caplin Steriles, Ltd.    		 Limited Limited supply; Check wholesalers for inventory; Marketed by Baxter
    In shortage · June 10, 2026

    + 34 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Sodium Acetate Anhydrous In shortage 5 products · updated October 27, 2026

    Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition, Other, Renal

    Product Availability Expected supply / notes
    Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66)
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · December 3, 2025
    Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02)
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · December 3, 2025
    Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67)
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · December 3, 2025

    + 2 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Bacitracin In shortage Some forms unavailable 1 product · updated October 23, 2026

    Anti-Infective, Ophthalmology

    Product Availability Expected supply / notes
    Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)
    Padagis US LLC    		 Unavailable Shortage is estimated for 15 additional months
    In shortage · October 23, 2026

    Uses, warnings and side effects from the FDA label →

  • Clonazepam In shortage Some forms unavailable 40 products · updated October 23, 2026

    Neurology, Pediatric, Psychiatry

    Product Availability Expected supply / notes
    Klonopin, Tablet, 2 mg (NDC 61269-620-10)
    Cheplapharm Arzneimittel GmbH    		 Unavailable Estimated duration February 2027. Manufacturing delays. Marketed by H2-Pharma.
    In shortage · October 16, 2026

    + 39 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Rifampin In shortage Some forms unavailable 13 products · updated October 23, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Rifampin, Capsule, 150 mg (NDC 42806-801-01)
    Epic Pharma, LLC    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · October 23, 2026
    Rifampin, Capsule, 300 mg (NDC 42806-799-30)
    Epic Pharma, LLC    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · October 23, 2026
    Rifampin, Capsule, 300 mg (NDC 42806-799-01)
    Epic Pharma, LLC    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · October 23, 2026
    Rifampin, Capsule, 300 mg (NDC 42806-799-05)
    Epic Pharma, LLC    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · October 23, 2026
    Rifampin, Injection, 600 mg (NDC 67457-445-60)
    Mylan Institutional, a Viatris Company    		 Unavailable Estimated recovery: Q4 2026
    In shortage · October 19, 2026
    Rifadin, Injection, 600 mg (NDC 0068-0597-01)
    Sanofi-Aventis U.S. LLC    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · September 18, 2026
    Rifampin, Injection, 600 mg (NDC 63323-351-20)
    Fresenius Kabi USA, LLC    		 Limited Check wholesalers for inventory
    In shortage · October 15, 2026
    Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · April 20, 2026

    + 5 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Metformin Hydrochloride Being discontinued 2 products · updated October 22, 2026

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Metformin Hydrochloride, Tablet, Extended Release, 500 mg (NDC 0378-6002-91)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 A business decision was made was discontinue manufacture of the drug product.
    Being discontinued · October 22, 2026
    Metformin Hydrochloride, Tablet, Extended Release, 1000 mg (NDC 0378-6001-91)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 A business decision was made was discontinue manufacture of the drug product.
    Being discontinued · October 22, 2026

    Uses, warnings and side effects from the FDA label →

  • Carboplatin In shortage Some forms unavailable 35 products · updated October 21, 2026

    Oncology

    Product Availability Expected supply / notes
    Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: December 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)
    Gland Pharma Limited    		 Unavailable Discontinued; Distributed by BPI Labs, LLC
    In shortage · October 21, 2026
    Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)
    Eugia US LLC    		 Unavailable On backorder. Recovery: late-October 2026. Check wholesalers for inventory
    In shortage · October 19, 2026
    Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: TBD/ NDC non-Exempt
    In shortage · October 17, 2026
    Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: TBD/ NDC non-Exempt
    In shortage · October 17, 2026
    Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: TBD/ NDC non-Exempt
    In shortage · October 17, 2026
    Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)
    Accord Healthcare Inc.    		 Unavailable Estimated recovery: TBD/ NDC non-Exempt
    In shortage · October 17, 2026
    Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)
    Teva Pharmaceuticals USA, Inc.    		 Unavailable Estimated recovery: January 2027
    In shortage · October 15, 2026
    Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)
    Fresenius Kabi USA, LLC    		 Unavailable Next release December 2026. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)
    Gland Pharma Limited    		 Limited Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC
    In shortage · October 21, 2026
    Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027
    In shortage · October 21, 2026
    Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)
    Gland Pharma Limited    		 Limited Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC
    In shortage · October 21, 2026
    Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)
    Teva Pharmaceuticals USA, Inc.    		 Limited Estimated recovery: December 2028
    In shortage · October 15, 2026
    Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)
    Teva Pharmaceuticals USA, Inc.    		 Limited Estimated recovery: March 2027
    In shortage · October 15, 2026
    Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)
    Teyro Labs    		 Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)
    Teyro Labs    		 Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)
    Teyro Labs    		 Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)
    Teyro Labs    		 Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)
    Ingenus Pharmaceuticals LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · February 20, 2026
    Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)
    Ingenus Pharmaceuticals LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · February 20, 2026

    + 9 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Clindamycin Phosphate In shortage Some forms unavailable 23 products · updated October 21, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)
    Pfizer Inc.    		 Unavailable Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)
    Pfizer Inc.    		 Unavailable Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)
    Pfizer Inc.    		 Unavailable Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)
    Sagent Pharmaceuticals    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · October 8, 2026
    Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)
    Baxter Healthcare    		 Limited Estimated recovery: December 2026
    In shortage · October 16, 2026
    Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)
    Sagent Pharmaceuticals    		 Limited Selling through remaining short-dated inventory (Dec 2026).
    In shortage · October 8, 2026
    Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)
    Sagent Pharmaceuticals    		 Limited Selling through remaining short-dated inventory (Dec 2026).
    In shortage · October 8, 2026
    Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026
    Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 1, 2026

    + 10 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Dexmedetomidine In shortage Some forms unavailable 8 products · updated October 21, 2026

    Anesthesia

    Product Availability Expected supply / notes
    Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)
    Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)    		 Unavailable Discontinuation of the manufacture of the drug; Distributed by Avenacy; Contact information: 877-283-6229
    In shortage · October 14, 2026
    Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)
    Accord Healthcare Inc.    		 Unavailable Discontinuation of the manufacture of the drug
    In shortage · September 15, 2026
    Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)
    Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)    		 Discontinuation of the manufacture of the drug; Distributed by Avenacy; Contact information: 877-283-6229
    Being discontinued · October 14, 2026
    Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)
    Accord Healthcare Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · April 21, 2026

    + 4 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate In shortage 4 products · updated October 21, 2026

    Psychiatry

    Product Availability Expected supply / notes
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)
    Sandoz Inc.    		 Available —
    In shortage · October 21, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)
    Sandoz Inc.    		 Available —
    In shortage · October 21, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)
    Sandoz Inc.    		 Available —
    In shortage · October 21, 2026
    Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)
    Sandoz Inc.    		 Available —
    In shortage · October 21, 2026

    Uses, warnings and side effects from the FDA label →

  • Dobutamine In shortage Some forms unavailable 4 products · updated October 21, 2026

    Cardiovascular, Pediatric, Renal

    Product Availability Expected supply / notes
    Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026

    + 3 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Dobutamine Hydrochloride In shortage 6 products · updated October 21, 2026

    Cardiovascular, Pediatric, Renal

    Product Availability Expected supply / notes
    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (2 mg/mL) (NDC 0409-0151-10)
    Hospira, Inc., a Pfizer Company    		 Available —
    In shortage · October 21, 2026
    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (1 mg/mL) (NDC 0409-0025-10)
    Hospira, Inc., a Pfizer Company    		 Available —
    In shortage · October 21, 2026
    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (4 mg/mL) (NDC 0409-1100-10)
    Hospira, Inc., a Pfizer Company    		 Available —
    In shortage · October 21, 2026
    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)
    Baxter Healthcare    		 Available —
    In shortage · October 16, 2026
    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)
    Baxter Healthcare    		 Available —
    In shortage · October 16, 2026
    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)
    Baxter Healthcare    		 Available —
    In shortage · October 16, 2026

    Uses, warnings and side effects from the FDA label →

  • Dopamine Hydrochloride In shortage Some forms unavailable 11 products · updated October 21, 2026

    Cardiovascular

    Product Availability Expected supply / notes
    Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
    In shortage · October 14, 2026
    Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe.
    In shortage · October 14, 2026
    Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026

    + 7 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Epinephrine In shortage Some forms unavailable 12 products · updated October 21, 2026

    Anesthesia, Pediatric, Cardiovascular, Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: January 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01)
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025
    Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10)
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025

    Uses, warnings and side effects from the FDA label →

  • Etomidate In shortage Some forms unavailable 18 products · updated October 21, 2026

    Anesthesia

    Product Availability Expected supply / notes
    Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)
    Hospira, Inc., a Pfizer Company    		 Unavailable Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
    In shortage · October 21, 2026
    Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)
    Mylan Institutional, a Viatris Company    		 Unavailable Estimated recovery: November 2026
    In shortage · October 19, 2026
    Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)
    Eugia US LLC    		 Unavailable On backorder. Recovery: TBD. Check wholesalers for inventory
    In shortage · October 19, 2026
    Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)
    Eugia US LLC    		 Unavailable On backorder. Recovery: TBD. Check wholesalers for inventory
    In shortage · October 19, 2026

    + 13 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Fentanyl Citrate In shortage Some forms unavailable 20 products · updated October 21, 2026

    Analgesia/Addiction, Pediatric

    Product Availability Expected supply / notes
    Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Inventory available in vial presentations.
    In shortage · October 14, 2026
    Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Inventory available in vial presentations.
    In shortage · October 14, 2026
    Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)
    Hikma Pharmaceuticals USA, Inc.    		 Unavailable Inventory available in vial presentations.
    In shortage · October 14, 2026
    Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026
    In shortage · October 21, 2026
    Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026
    In shortage · October 21, 2026
    Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)
    Hospira, Inc., a Pfizer Company    		 Limited Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026
    In shortage · October 21, 2026

    + 14 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

  • Heparin Sodium In shortage Some forms unavailable 8 products · updated October 21, 2026

    Hematology

    Product Availability Expected supply / notes
    Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)
    Fresenius Kabi USA, LLC    		 Unavailable Next release November 2026. Check wholesalers for inventory.
    In shortage · October 15, 2026
    Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)
    B. Braun Medical Inc.    		 Limited Estimated recovery: late Q4 2026; Manufacturing delays
    In shortage · October 19, 2026
    Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)
    B. Braun Medical Inc.    		 Limited Estimated recovery: late Q4 2026; Manufacturing delays
    In shortage · October 19, 2026
    Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)
    Baxter Healthcare    		 Limited Estimated recovery: December 2026
    In shortage · October 16, 2026

    + 4 more products listed, currently available.

    Uses, warnings and side effects from the FDA label →

Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.

Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.

Advertisement